Cholinergic Receptors in Aging and Alzheimers Disease Ligand Neuroimaging

衰老和阿尔茨海默病配体神经影像中的胆碱能受体

• 批准号: 8044579
• 负责人: David Sultzer
• 金额: --
• 依托单位: VA GREATER LOS ANGELES HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8044579
• 关键词: Address; Affect; Age; Aging; Alzheimer' s Disease; Amyloid beta-Protein; Amyloid deposition; Atrophic; Attention; Attention Concentration; Binding; Biological Markers; Brain; Brain imaging; Brain region; Cerebral cortex; Chemicals; Cholinergic Receptors; Cholinesterase Inhibitors; Clinical; Clinical assessments; Cognition; Cognition Disorders; Cognitive; Cognitive deficits; Data; Degenerative Disorder; Deposition; Development; Diffuse; Disease; Disease Progression; Elderly; Event; Functional disorder; Future; Goals; Health; Healthcare; Human; Image; Imaging Device; Imaging Techniques; Impaired cognition; Individual; Intervention; Kinetics; Lead; Ligands; Link; Measures; Medial; Mediating; Memory; Memory impairment; Molecular; Monitor; Morbidity - disease rate; Neurobiology; Neurotransmitters; Nicotinic Agonists; Nicotinic Receptors; Parietal Lobe; Participant; Pathogenesis; Pathology; Pathway interactions; Patients; Pharmaceutical Preparations; Play; Population; Positron-Emission Tomography; Prevalence; Process; Production; Proteins; Public Health; Relative (related person); Research; Research Project Grants; Risk; Role; Sampling; Senile Plaques; Sensory Receptors; Severity of illness; Structure; Symptoms; System; Tauopathies; Techniques; Temporal Lobe; Thalamic structure; Therapeutic Intervention; Thinking; Time; Toxic effect; Veterans; Work; amyloid precursor protein processing; association cortex; basal forebrain; base; brain tissue; cellular pathology; cholinergic; density; effective therapy; experience; frontal lobe; functional status; improved; in vivo; mild neurocognitive impairment; neuroimaging; neuropathology; neurotransmission; novel; processing speed; pyridine; receptor; receptor binding; receptor density; response; skills; therapy development; tool; treatment effect; treatment strategy

DESCRIPTION (provided by applicant): The overall goal of this project is to assess cholinergic receptor density in Alzheimer's disease (AD) and mild cognitive impairment (MCI) using positron emission tomography (PET) imaging. AD causes enormous morbidity and is becoming a major healthcare problem among veterans as the population ages. Several distinct neuropathological events occur in AD. The relative contribution of each event to clinical symptoms and disease progression is unclear, and developing effective treatments based on known abnormal proteins and processes in AD has been elusive. Currently, there are few tools available to study neuropathology or disease expression in vivo. Altered cholinergic neurotransmission is a core neurobiological feature of AD. In recent years, AD research has focused largely on other cellular and molecular events, such as beta-amyloid production and deposition. Nonetheless, recent work continues to support a critical role for the cholinergic receptor system in AD - as a "primary" AD pathology, via interactions with neuropathological proteins such as beta-amyloid, or by mediating the expression of cognitive deficits. Recently, the PET ligand 2-18F-fluoro-3-(2(S)azetidinylmethoxy) pyridine (2-FA) was developed to measure regional nicotinic 1422 receptors (nAChR) in vivo. The improved technique is safe for use in humans, and is sensitive and reliable. There is limited experience with its use in AD, although preliminary studies by our group and others suggest that cortical nAChRs can be measured accurately in AD, and binding is reduced in AD and lower density may be associated with cognitive deficits. The proposed project uses 2-FA PET imaging to compare nAChR binding in AD patients and healthy older adults. Three related questions are addressed: 1) What is the extent of reduced nAChRs in AD? Are alterations present in those with MCI and at risk for progression to AD?, 2) Where in the brain are nAChRs abnormal in AD?, and 3) Are regional reductions in nAChR binding in AD associated with global cognitive impairment or with specific deficits in memory or attention? To answer these questions, patients with mild to moderate AD, those with amnestic MCI, and healthy older adults will undergo clinical assessment and 2-FA PET imaging. We will compare global and regional nAChR binding between the groups and examine the association between regional nAChR binding in whole brain, temporal cortex, and frontal cortex, and measures of global cognition, memory, and attention. The MCI group will be followed for two years and the relationship between baseline nAChR binding and subsequent change in cognition will be assessed. Results of this study can define the extent of reduced nAChRs in specific brain regions in AD and MCI in vivo and their contribution to global and distinct cognitive deficits. The study also advances 2-FA imaging as a biomarker for cholinergic dysfunction in AD and MCI that can be used in future studies to identify very early cholinergic changes in AD, measure change over time, evaluate associations with other AD neuropathologies, assess response to therapeutic interventions, and provide a target for new medication development PUBLIC HEALTH RELEVANCE: This research project is a study of people with Alzheimer's disease and with "mild cognitive impairment". In mild cognitive impairment, memory is impaired but not to the extent of Alzheimer's disease. The research project uses brain imaging to measure a type of chemical receptor in the brain that is very important for memory and thinking. These receptors are probably abnormal in Alzheimer's disease and the research project examines how abnormal they are, where in the brain they are prominently abnormal, and how their abnormality is related to memory problems and other cognitive difficulties. The project is relevant to veterans' health in that it can define better what is abnormal in the brain of veterans with Alzheimer's disease, and can explain why veterans with Alzheimer's disease have memory problems. This information can be used to help identify treatment strategies that can reverse the receptor abnormality, and brain imaging can be used to monitor treatment effects on these important receptors to improve the health of veterans.

描述（由申请人提供）：